Discussion stirs around Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) this week; here is what analysts are saying.

June 19, 2017 - By Adrian Erickson

 Discussion stirs around Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) this week; here is what analysts are saying.
Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.22, from 1.1 in 2016Q3. It dived, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. 46 funds opened positions while 141 raised stakes. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported.
Chevy Chase Trust holds 0.09% or 234,540 shares. Eqis Cap Mngmt invested in 0.07% or 16,142 shares. Blackrock has 0.07% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 687,506 shares. First Light Asset Mgmt, a Minnesota-based fund reported 23,225 shares. Cibc World Mkts Corp invested in 0.01% or 17,047 shares. Henderson Group Public Limited Company reported 0.02% stake. Clearbridge Llc holds 0% or 650 shares in its portfolio. Ubs Asset Management Americas holds 0.18% or 2.24M shares. Brinker Cap invested in 11,877 shares or 0.05% of the stock. Holland Cap Management Ltd reported 278,912 shares. D E Shaw & Co Incorporated reported 637,583 shares stake. Liberty Mutual Grp Inc Asset Mngmt Inc holds 18,099 shares or 0.05% of its portfolio. Stevens Mgmt Limited Partnership reported 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sumitomo Mitsui Asset Ltd owns 18,674 shares for 0.03% of their portfolio. Weiss Multi reported 24,117 shares stake.

Since December 21, 2016, it had 0 insider purchases, and 32 selling transactions for $69.98 million activity. On Wednesday, January 4 the insider BOGER JOSHUA S sold $501,319. The insider Arbuckle Stuart A sold $335,175. $249,384 worth of stock was sold by Chodakewitz Jeffrey on Monday, April 3. The insider SMITH IAN F sold $345,780. 30,500 shares valued at $3.81M were sold by Sachdev Amit on Thursday, June 1. Bhatia Sangeeta N. had sold 1,176 shares worth $151,045 on Thursday, June 1. LEIDEN JEFFREY M had sold 23,904 shares worth $2.10 million on Monday, February 13.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 17 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 11 have Buy rating, 0 Sell and 6 Hold. Therefore 65% are positive. Vertex Pharmaceuticals had 37 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Friday, October 2. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Wednesday, March 1 by Citigroup. The firm has “Buy” rating by Nomura given on Wednesday, September 16. Oppenheimer initiated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, December 15 with “Perform” rating. Raymond James initiated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, September 13 with “Mkt Perform” rating. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Argus Research on Thursday, February 4. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Overweight” rating by Barclays Capital on Monday, September 14. Goldman Sachs downgraded the shares of VRTX in report on Thursday, April 28 to “Neutral” rating. The company was maintained on Thursday, September 15 by Stifel Nicolaus. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

02/06/2017 Broker: Oppenheimer Old Rating: Perform New Rating: Outperform Upgrade
29/03/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Upgrade
17/03/2017 Broker: JMP Securities Old Rating: Market Perform New Rating: Market Outperform Upgrade
01/03/2017 Broker: Citigroup Rating: Buy New Target: $105 Initiate
26/01/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $108 New Target: $100 Maintain

About 522,980 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since June 19, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $31.04 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 177.3 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

Another recent and important Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news was published by Nasdaq.com which published an article titled: “Zacks.com featured highlights: Salesforce.com, Vertex Pharmaceuticals, Live …” on June 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.